18F-FDG PET/CT 在 CT 引导肺活检中的解剖与代谢引导作用
回顾性分析 340 例连续患者共 353 次 CT 引导经皮肺穿刺活检,比较活检前 PET/CT、活检后 PET/CT 与未行 PET/CT 三组的诊断率与安全性。活检前 PET/CT 组活检成功率 88.8%,高于未行 PET/CT 组的 78.9%(p<0.01);穿刺目标为 PET/CT 最大活性区者成功率 88.8%,未 targeting 该区者仅 52.8%(p<0.0001)。
要点
- 活检前 PET/CT 组活检成功率 88.8%,未行 PET/CT 组 78.9%(p<0.01)。
- 穿刺目标为 PET/CT 最大活性区者成功率 88.8%,未 targeting 者 52.8%(p<0.0001)。
- 肿块患者活检前有 PET/CT 者成功率显著提高(OR 7.01,p=0.004),结节或多发结节组无显著差异。
核心结论
- 18F-FDG PET/CT 提供的代谢信息及将穿刺定位到 PET/CT 最大活性区与更高的活检诊断率相关,尤其在肿块患者中,且活检前获得 PET/CT 似乎可减少穿刺次数和并发症。
研究设计与样本
- 回顾性分析 340 例连续可疑肺结节、肿块或广泛病变患者,3 年内共行 353 次经皮肺穿刺活检,按活检前 PET/CT、活检后 PET/CT 和未行 PET/CT 分为三组,与组织病理结果对照。
诊断标准与关键数值
- 总体诊断率 83.9%(其中 95.8% 为恶性);病灶中位大小 30 mm(范围 7–120 mm)。
- 活检前 PET/CT 组活检成功率 88.8%,未行 PET/CT 组 78.9%(p<0.01,Fisher 精确检验)。
- 穿刺目标为 PET/CT 最大活性区者活检成功率 88.8%,未 targeting 该区者 52.8%(p<0.0001)。
- 活检前 PET/CT 组 targeting 最大活性区比例 91.0%,活检后 PET/CT 组 80.0%(p=0.01)。
- 肿块患者活检前有 PET/CT 者活检成功率提高(OR 7.01,p=0.004),结节组 p=0.498、多发结节组 p=0.163 无显著差异。
临床应用与阅片要点
- 活检前 PET/CT 组平均穿刺次数 2.6 次,未行 PET/CT 组 3.1 次(p<0.0001,Mann-Whitney U 检验)。
- 活检前 PET/CT 组严重并发症发生率 4.5%,未行 PET/CT 组 10.9%(p<0.05)。
- 活检前 PET/CT 的获益见于全部 3 位放射科医生,以肿块和浸润性病变最为明显。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the role of Fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT as a metabolic guide in increasing the accuracy, diagnostic yield and safety of CT-guided percutaneous needle lung biopsy (PNB).
METHODS AND MATERIALS: Retrospective analysis of 340 consecutive patients with suspicious lung nodules, masses or extensive disease that underwent lung biopsy over a 3-year period. Patients were divided into three groups; those that had PET/CT prior to the biopsy, those that had PET-CT following the biopsy and those who did not undergo PET-CT. Correlation was made with the histopathological result.
RESULTS: 353 PNBs were performed (median lesion size 30 mm, 7-120 mm) with overall diagnostic rate of 83.9 % (95.8 % malignant). Biopsy success rate was 88.8 % with PET-CT pre-PNB, versus 78.9 % of 175 PNB without PET-CT upfront (p < 0.01 Fisher exact test). Correct targeting to PET-CT-maximum activity area (MAA) was present in 87.1 %. Biopsy success rate was 88.8 % for PNBs targeting the PET-CT-MAA region and only 52.8 % for PNBs not targeting the PET-CT-MAA (p < 0.0001). PET-CT pre-PNB had higher rates of PET-CT-MAA targeting compared to PET-CT post PNB (91.0 % v 80.0 %, p = 0.01). The availability of PET-CT before the PNB lead to significantly increased biopsy success rates in patients with a mass (OR:7.01p = 0.004), compared to a nodule (p = 0.498) or multiple nodules (p = 0.163). Patients with a PET-CT pre-PNB underwent fewer PNB passes (mean 2.6 v 3.1, p < 0.0001 Mann Whitney U). Serious complications were less common in PET-CT pre-PNB group (4.5 % v 10.9 %, p < 0.05). Pre-PNB PET-CT performance improvement applied to all 3 radiologists and was greatest for masses and infiltrative abnormalities.
CONCLUSION: Metabolic information provided by 18F-FDG PET/CT and PNB localisation to the PET-CT maximum activity region is associated with higher diagnostic biopsy rates especially in masses and appears to account for improved performance, less needle passes and complications when available pre-biopsy.
引用
- Stefanidis K, Bellos I, Konstantelou E, et al. 18F-FDG PET/CT anatomic and metabolic guidance in CT-guided lung biopsies. Eur J Radiol. 2024. PMID: 38237515. doi:10.1016/j.ejrad.2024.111315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。